Compare JetBlue Airways Corporation (JBLU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? JetBlue Airways Corporation trades at $5.4 (market cap $2.03B), while Vertex Pharmaceuticals Incorporated trades at $480.74 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 60.1× JetBlue Airways Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| JBLU | VRTX | |
|---|---|---|
Market Cap | $2.03B | $121.95B |
Sector | Industrials | Health |
52-Week High | $6.46 | $529.59 |
52-Week Low | $4.03 | $366.54 |
Enterprise Value | $9.19B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.45, up 0.55% today, with technical indicators showing a neutral bias despite recent earnings misses. The airline reported a net loss of $602 million in 2025 with negative profit margins, though valuation metrics like P/S of 0.22 appear attractive. Recent news highlights expansion at Fort Lauderdale and new payment partnerships, while analyst consensus remains cautious with a $5.12 price target.
JBLU faces significant challenges with persistent losses and high debt levels, though strategic expansions and cost management efforts provide some optimism. The stock trades near analyst targets with mixed sentiment, requiring careful monitoring of upcoming Q2 2026 earnings and fuel cost trends for directional clarity.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
